Apellis Pharmaceuticals Inc (APLS)
50.62
+2.69
(+5.61%)
USD |
NASDAQ |
Apr 26, 12:11
Apellis Pharmaceuticals Enterprise Value: 5.521B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 5.521B |
| April 24, 2024 | 5.762B |
| April 23, 2024 | 5.617B |
| April 22, 2024 | 5.486B |
| April 19, 2024 | 5.473B |
| April 18, 2024 | 5.471B |
| April 17, 2024 | 5.533B |
| April 16, 2024 | 5.990B |
| April 15, 2024 | 5.952B |
| April 12, 2024 | 5.987B |
| April 11, 2024 | 6.462B |
| April 10, 2024 | 6.596B |
| April 09, 2024 | 6.388B |
| April 08, 2024 | 6.230B |
| April 05, 2024 | 6.484B |
| April 04, 2024 | 6.500B |
| April 03, 2024 | 6.609B |
| April 02, 2024 | 6.458B |
| April 01, 2024 | 6.942B |
| March 28, 2024 | 6.830B |
| March 27, 2024 | 6.795B |
| March 26, 2024 | 6.856B |
| March 25, 2024 | 6.438B |
| March 22, 2024 | 6.421B |
| March 21, 2024 | 6.568B |
| Date | Value |
|---|---|
| March 20, 2024 | 6.437B |
| March 19, 2024 | 6.605B |
| March 18, 2024 | 6.526B |
| March 15, 2024 | 6.584B |
| March 14, 2024 | 6.552B |
| March 13, 2024 | 6.658B |
| March 12, 2024 | 6.796B |
| March 11, 2024 | 7.060B |
| March 08, 2024 | 7.173B |
| March 07, 2024 | 7.271B |
| March 06, 2024 | 7.090B |
| March 05, 2024 | 7.275B |
| March 04, 2024 | 7.535B |
| March 01, 2024 | 7.446B |
| February 29, 2024 | 7.214B |
| February 28, 2024 | 7.465B |
| February 27, 2024 | 8.104B |
| February 26, 2024 | 8.391B |
| February 23, 2024 | 7.998B |
| February 22, 2024 | 7.892B |
| February 21, 2024 | 7.808B |
| February 20, 2024 | 7.923B |
| February 16, 2024 | 7.965B |
| February 15, 2024 | 7.821B |
| February 14, 2024 | 7.799B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
856.61M
Minimum
May 17 2019
10.19B
Maximum
Jun 13 2023
4.062B
Average
3.732B
Median
Enterprise Value Benchmarks
| Sarepta Therapeutics Inc | 11.52B |
| Blueprint Medicines Corp | 5.084B |
| Alnylam Pharmaceuticals Inc | 16.68B |
| Ionis Pharmaceuticals Inc | 5.050B |
| Madrigal Pharmaceuticals Inc | 3.349B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -88.58M |
| Revenue (Quarterly) | 146.38M |
| Total Expenses (Quarterly) | 230.90M |
| EPS Diluted (Quarterly) | -0.73 |
| Gross Profit Margin (Quarterly) | 86.40% |
| Profit Margin (Quarterly) | -60.51% |
| Earnings Yield | -8.85% |
| Normalized Earnings Yield | -8.850 |